Press Releases | Regeneron Pharmaceuticals Inc.
WEBDupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) Sep 26. Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024. Sep 20.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Regeneron Reports Second Quarter 2024 Financial and Operating …
WEBAug 1, 2024 · Second quarter 2024 revenues increased 12% to $3 .55 billion versus second quarter 2023 Second quarter 2024 Dupixent ® global net sales (recorded by Sanofi) increased 27% to $3 .56 billion versus second quarter 2023 Second quarter 2024 U.S. net sales for EYLEA ® HD and EYLEA ® increased 2% to $1
News Release - Regeneron Pharmaceuticals Inc.
WEBFirst quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022. First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2 .49 billion versus first quarter 2022. First quarter 2023 EYLEA® U.S. …
Regeneron's blood cancer therapy faces setback as FDA raises …
WEBMar 25, 2024 · Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing confirmatory trials.
Regeneron Pharmaceuticals: Delivering Life-transforming Medicines
WEBRegeneron News: Sep 27th. Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
US FDA approves Regeneron's ultra-rare blood disease drug
WEBAug 18 (Reuters) - Regeneron Pharmaceuticals (REGN.O) said on Friday the U.S. health regulator approved its drug to treat a rare blood disease. The drug pozelimab, branded as Veopoz, would treat...
Sanofi/Regeneron’s Dupixent approved by FDA to treat …
WEB2 days ago · Approximately 300,000 patients in the US will be eligible for the therapy. Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulator’s decision, which makes Dupixent the first biologic medicines ...
Regeneron Shares Head for Worst Month Since 2019 on Legal …
WEBSep 27, 2024 · AMGN. (Bloomberg) -- Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2019 after a legal setback that opens the door to an early launch of a competing ...
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® …